Phase I trials of antitumour agents: Fundamental concepts

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  De Araujo Toloi, Diego ^a,b   Jardim, Denis Leonardo Fontes ^a,b   Hoff, Paulo Marcelo Gehm ^a,b   Riechelmann, Rachel Simões Pimenta ^a,b  

^a Department of Medical Oncology   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Combination therapy; Molecular targeted drugs; Oncology; Phase i study

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER THERAPY; CLINICAL RESEARCH; HUMAN; LIFE EXPECTANCY; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC);

EID: 84921783753     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.501     Document Type: Article

References (26)

1. Umscheid CA, Margolis DJ and Grossman CE (2011) Key concepts of clinical trials: a narrative review Postgrad Med 123(5) 194-204 DOI: 10.3810/pgm.2011.09.2475 PMID: 21904102 PMCID: 3272827
2. Chabner BA (2011) Early approval for highly targeted cancer Drugs N Engl J Med 364(12) 1087-89 DOI: 10.1056/NEJMp11 00548 PMID: 21428763
3. LoRusso PM, Boerner SA and Seymour L (2010) An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics Clin Cancer Res 16(6) 1710-18 DOI: 10.1158/1078-0432.CCR-09-1993 PMID: 20215546
4. Internet: Agência Nacional de Vigilância Sanitária and Ministério da Saúde. Boas Práticas Clínicas (2005) Documento das Américas. IV Conferência Pan-Americana para Harmonização da Regulamentação Farmacêutica República Dominicana available at: http://www.anvisa.gov.br/medicamentos/pesquisa/boaspraticas-americas.pdf
5. Ivy SP, Siu LL and Garret-Mayer E (2010) Approaches do phase I clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee Clin Cancer Res 16(6) 1726-36 DOI: 10.1158/1078-0432.CCR-09-1961 PMID: 20215542
6. Sleijfer S and Wiemer E (2008) Dose selection in phase I studies: why we should always go for the top J Clin Oncol 26(10) 1576-78 DOI: 10.1200/JCO.2007.15.5192 PMID: 18332465
7. Mandrekar SJ, Qin R and Sargent DJ (2010) Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges Stat Med 29(10) 1077-83 DOI: 10.1002/sim.3706 PMID: 20419760 PMCID: 2931331
8. Booth CM et al (2008) On behalf of the task force on methodology for the development of innovative cancer therapies. endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT) Eur J Cancer (44) 19-24 DOI: 10.1016/j. ejca.2007.07.034
9. Tolcher AW, Takimoto CH and Rowinsky EK (2002) The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"? J Clin Oncol 20(21) 4276-78 PMID: 12409324
10. Skolnik JM et al (2008) Shortening the timeline of pediatric phase I trials: the rolling six design J Clin Oncol 26(2) 190-95 DOI: 10.1200/JCO.2007.12.7712 PMID: 18182661
11. Le Tourneau C, Lee JJ and Siu LL(2009) Dose escalation methods in phase I cancer clinical trials J Natl Cancer Inst 101 (10) 708-20 DOI: 10.1093/jnci/djp079 PMID: 19436029 PMCID: 2684552
12. Iasonos A and O'Quigley J (2014) Adaptive dose-finding studies: a review of model-guided phase I clinical trials J Clin Oncol 32(23) 2505-11 DOI: 10.1200/JCO.2013.54.6051 PMID: 24982451 PMCID: 4121508
13. Manji A et al (2013) Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials J Clin Oncol 31(33) 4260-7 DOI: 10.1200/JCO.2012.47.4957 PMID: 24127441
14. Hyman DM et al (2014) Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials J Clin Oncol 32(6) 519-26 DOI: 10.1200/JCO.2013.49.8808 PMID: 24419130 PMCID: 3918535
15. Bedard PL and Siu LL (2014) Tilting the balance of dose modification for oral anticancer drugs? J Clin Oncol 32(15) 1537-9 DOI: 10.1200/JCO.2014.55.2372 PMID: 24711547
16. Postel-Vinay S et al (2011) Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol 29(13) 1728-35 DOI: 10.1200/JCO.2010.31.9236 PMID: 21444876
17. Wagesa NA, Conawayb MR and O'Quigley J (2011) Dose-finding design for multi-drug combinations Clin Trials 8(4) 380-89 DOI: 10.1177/1740774511408748
18. Horstmann E et al (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002 N Engl J Med 352(9) 895-904 DOI: 10.1056/NEJMsa042220 PMID: 15745980
19. Jardim DLF et al (2014) Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs Clin Cancer Res 20(2) 281-8 DOI: 10.1158/1078-0432.CCR-13-2103
20. Tsimberidou AM et al (2012) Personalized medicine in phase I clinical trials program: the MD Anderson Cancer Center initiative Clin Cancer Res 18(22) 6373-83 DOI: 10.1158/1078-0432.CCR-12-1627 PMID: 22966018
21. Jain RK et al (2010) Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse Clin Cancer Res 16(4) 1289-97 DOI: 10.1158/1078-0432.CCR-09-2684 PMID: 20145187 PMCID: 2822881
22. Ryan CJ et al (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J Clin Oncol 28(9) 1481-88 DOI: 10.1200/ JCO.2009.24.1281 PMID: 20159824 PMCID: 2849769
23. Tai WMD et al (2013) Do elderly patients benefit from enrollment in phase I clinical trials? J Clin Oncol (suppl abstr 9509)
24. Schwandt A et al (2014) The role of age on dose-limiting toxicities in phase I dose-escalation trials Clin Cancer Res 20(18) 4768-75 DOI: 10.1158/1078-0432.CCR-14-0866
25. Henderson GE (2007) et al Clinical trials and medical care: defining the therapeutic misconception PLoS Med 4(11) e324 DOI: 10.1371/journal.pmed.0040324 PMID: 18044980 PMCID: 2082641
26. Agrawal M and Emanuel EJ (2003) Ethics of phase 1 oncology studies: reexamining the arguments and data JAMA 290(8) 1075-82 DOI: 10.1001/jama.290.8.1075 PMID: 12941681